Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) Is 59.13% Above Its 52-Week Low, But How Long Will It Remain So?

IPW

In last trading session, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw 1.05 million shares changing hands with its beta currently measuring 1.39. Company’s recent per share price level of $12.60 trading at $1.59 or 14.44% at ring of the bell on the day assigns it a market valuation of $1.27B. That closing price of CNTA’s stock is at a premium of 1.19% from its 52-week high price of $12.45 and is indicating a premium of 59.13% from its 52-week low price of $5.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 243.22K if we extend that period to 3-months.

For Centessa Pharmaceuticals plc ADR (CNTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information

Upright in the green during last session for gaining 14.44%, in the last five days CNTA remained trading in the green while hitting it’s week-highest on Wednesday, 08/14/24 when the stock touched $12.60 price level, adding 2.63% to its value on the day. Centessa Pharmaceuticals plc ADR’s shares saw a change of 58.29% in year-to-date performance and have moved 15.49% in past 5-day. Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) showed a performance of 26.89% in past 30-days. Number of shares sold short was 1.38 million shares which calculate 5.21 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 16.0% to its current value. Analysts have been projecting 15 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would drop -19.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -19.05% for stock’s current value.

Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts

Statistics highlight that Centessa Pharmaceuticals plc ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company added 32.63% of value to its shares in past 6 months, showing an annual growth rate of -3.18% while that of industry is 17.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders

Insiders are in possession of 1.84% of company’s total shares while institution are holding 78.03 percent of that, with stock having share float percentage of 79.50%. Investors also watch the number of corporate investors in a company very closely, which is 78.03% institutions for Centessa Pharmaceuticals plc ADR that are currently holding shares of the company. MEDICXI VENTURES MANAGEMENT (JERSEY) LTD is the top institutional holder at CNTA for having 19.96 million shares of worth $225.58 million. And as of 2024-03-31, it was holding 20.7566 of the company’s outstanding shares.

The second largest institutional holder is GENERAL ATLANTIC, L.P., which was holding about 9.68 million shares on 2024-03-31. The number of shares represents firm’s hold over 10.0666 of outstanding shares, having a total worth of $109.4 million.